|
1
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leonessa F and Clarke R: ATP binding
cassette transporters and drug resistance in breast cancer. Endocr
Relat Cancer. 10:43–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ling V: Multidrug resistance: Molecular
mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40
(Suppl):S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakaeda T, Nakamura T and Okumura K:
Pharmacogenetics of drug transporters and its impact on the
pharmacotherapy. Curr Top Med Chem. 4:1385–1398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arnal M, Franco N, Fargeot P, Riedinger
JM, Brunet-Lecomte P and Lizard-Nacol S: Enhancement of mdr1 gene
expression in normal tissue adjacent to advanced breast cancer.
Breast Cancer Res Treat. 61:13–20. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mairinger S, Erker T, Muller M and Langer
O: PET and SPECT radiotracers to assess function and expression of
ABC transporters in vivo. Curr Drug Metab. 12:774–792. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Charpin C, Vielh P, Duffaud F, Devictor B,
Andrac L, Lavaut MN, Allasia C, Horschowski N and Piana L:
Quantitative immunocytochemical assays of P-glycoprotein in breast
carcinomas: Correlation to messenger RNA expression and to
immunohistochemical prognostic indicators. J Natl Cancer Inst.
86:1539–1545. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vaclavikova R, Nordgard SH, Alnaes GI,
Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I,
Kristensen VN and Soucek P: Single nucleotide polymorphisms in the
multidrug resistance gene 1 (ABCB1): Effects on its expression and
clinicopathological characteristics in breast cancer patients.
Pharmacogenet Genomics. 18:263–273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ehrlichova M, Mohelnikova-Duchonova B,
Hrdy J, Brynychova V, Mrhalova M, Kodet R, Rob L, Pluta M, Gut I,
Soucek P and Vaclavikova R: The association of taxane resistance
genes with the clinical course of ovarian carcinoma. Genomics.
102:96–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnatty SE, Beesley J, Gao B, Chen X, Lu
Y, Law MH, Henderson MJ, Russell AJ, Hedditch EL, Emmanuel C, et
al: ABCB1 (MDR1) polymorphisms and ovarian cancer progression and
survival: A comprehensive analysis from the ovarian cancer
association consortium and the cancer genome atlas. Gynecol Oncol.
131:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lili X and Xiaoyu T: Expression of PKCα,
PKCε, and P-gp in epithelial ovarian carcinoma and the clinical
significance. Eur J Gynaecol Oncol. 36:181–185. 2015.PubMed/NCBI
|
|
12
|
Burger H, Foekens JA, Look MP, Meijer-van
Gelder ME, Klijn JG, Wiemer EA, Stoter G and Nooter K: RNA
expression of breast cancer resistance protein, lung
resistance-related protein, multidrug resistance-associated
proteins 1 and 2, and multidrug resistance gene 1 in breast cancer:
Correlation with chemotherapeutic response. Clin Cancer Res.
9:827–836. 2003.PubMed/NCBI
|
|
13
|
Chintamani, Singh JP, Mittal MK, Saxena S,
Bansal A, Bhatia A and Kulshreshtha P: Role of p-glycoprotein
expression in predicting response to neoadjuvant chemotherapy in
breast cancer-a prospective clinical study. World J Surg Oncol.
3:612005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Surowiak P, Materna V, Matkowski R,
Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert
C, Zabel M and Lage H: Relationship between the expression of
cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers
and their prognostic significance. Breast Cancer Res. 7:R862–R870.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu L, Katsaros D, Wiley A, Rigault de la
Longrais IA, Puopolo M and Yu H: Expression of MDR1 in epithelial
ovarian cancer and its association with disease progression. Oncol
Res. 16:395–403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tabolacci E and Chiurazzi P: Epigenetics,
fragile X syndrome and transcriptional therapy. Am J Med Genet A
161A. 2797–2808. 2013. View Article : Google Scholar
|
|
18
|
O'Hagan HM, Mohammad HP and Baylin SB:
Double strand breaks can initiate gene silencing and
SIRT1-dependent onset of DNA methylation in an exogenous promoter
CpG island. PLoS Genet. 4:e10001552008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tabish AM, Poels K, Hoet P and Godderis L:
Epigenetic factors in cancer risk: Effect of chemical carcinogens
on global DNA methylation patternin human TK6 cells. PLoS One.
7:e346742012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muggerud AA, Rønneberg JA, Wärnberg F,
Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I,
Børresen-Dale AL, Kristensen VN, et al: Frequent aberrant DNA
methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma
in situ and early invasive breast cancer. Breast Cancer Res.
12:R32010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dejeux E, Rønneberg JA, Solvang H, Bukholm
I, Geisler S, Aas T, Gut IG, Børresen-Dale AL, Lønning PE,
Kristensen VN and Tost J: DNA methylation profiling in doxorubicin
treated primary locally advanced breast tumours identifies novel
genes associated with survival and treatment response. Mol Cancer.
9:682010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klajic J, Fleischer T, Dejeux E, Edvardsen
H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen-Dale AL,
Tost J and Kristensen VN: Quantitative DNA methylation analyses
reveal stage dependent DNA methylation and association to
clinico-pathological factors in breast tumors. BMC Cancer.
13:4562013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma G, Mirza S, Parshad R, Srivastava
A, Datta Gupta S, Pandya P and Ralhan R: CpG hypomethylation of
MDR1 gene in tumor and serum of invasive ductal breast carcinoma
patients. Clin Biochem. 43:373–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharma G, Mirza S, Parshad R, Gupta SD and
Ralhan R: DNA methylation of circulating DNA: A marker for
monitoring efficacy of neoadjuvant chemotherapy in breast cancer
patients. Tumour Biol. 33:1837–1843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Enokida H, Shiina H, Igawa M, Ogishima T,
Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, et
al: CpG hypermethylation of MDR1 gene contributes to the
pathogenesis and progression of human prostate cancer. Cancer Res.
64:5956–5962. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vaclavikova R, Ehrlichova M, Hlavata I,
Pecha V, Kozevnikovova R, Trnkova M, Adamek J, Edvardsen H,
Kristensen VN, Gut I and Soucek P: Detection of frequent ABCB1
polymorphisms by high-resolution melting curve analysis and their
effect on breast carcinoma prognosis. Clin Chem Lab Med.
50:1999–2007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klajic J, Busato F, Edvardsen H, Touleimat
N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J and
Kristensen VN: DNA methylation status of key cell-cycle regulators
such as CDKNA2/p16 and CCNA1 correlates with treatment response to
doxorubicin and 5-fluorouracil in locally advanced breast tumors.
Clin Cancer Res. 20:6357–6366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aas T, Børresen AL, Geisler S,
Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE:
Specific P53 mutations are associated with de novo resistance to
doxorubicin in breast cancer patients. Nat Med. 2:811–814. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geisler S, Lønning PE, Aas T, Johnsen H,
Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Børresen-Dale AL:
Influence of TP53 gene alterations and c-erbB-2 expression on the
response to treatment with doxorubicin in locally advanced breast
cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI
|
|
30
|
Geisler S, Børresen-Dale AL, Johnsen H,
Aas T, Geisler J, Akslen LA, Anker G and Lønning PE: TP53 gene
mutations predict the response to neoadjuvant treatment with
5-fluorouracil and mitomycin in locally advanced breast cancer.
Clin Cancer Res. 9:5582–5588. 2003.PubMed/NCBI
|
|
31
|
Brynychová V, Hlaváč V, Ehrlichová M,
Václavíková R, Pecha V, Trnková M, Wald M, Mrhalová M, Kubáčková K,
Pikus T, et al: Importance of transcript levels of caspase-2
isoforms S and L for breast carcinoma progression. Future Oncol.
9:427–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elsnerova K, Mohelnikova-Duchonova B,
Cerovska E, Ehrlichova M, Gut I, Rob L, Skapa P, Hruda M, Bartakova
A, Bouda J, et al: Gene expression of membrane transporters:
Importance for prognosis and progression of ovarian carcinoma.
Oncol Rep. 35:2159–2170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tost J and Gut IG: DNA methylation
analysis by pyrosequencing. Nat Protoc. 2:2265–2275. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Soucek P, Anzenbacher P, Skoumalová I and
Dvorák M: Expression of cytochrome P450 genes in CD34+
hematopoietic stem and progenitor cells. Stem Cells. 23:1417–1422.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th. Springer;
Cham, Switzerland: 2017, View Article : Google Scholar
|
|
38
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Václavíková R, Boumendjel A, Ehrlichová M,
Kovár J and Gut I: Modulation of paclitaxel transport by flavonoid
derivatives in human breast cancer cells. Is there a correlation
between binding affinity to NBD of P-gp and modulation of
transport? Bioorg Med Chem. 14:4519–4525. 2006.
|
|
40
|
Němcová-Fürstová V, Kopperová D,
Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, Daniel P,
Souček P and Kovář J: Characterization of acquired paclitaxel
resistance of breast cancer cells and involvement of ABC
transporters. Toxicol Appl Pharmacol. 310:215–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
